Factors Affecting the Comprehension of Outpatients Receiving Cancer Chemotherapy
Pharmaceutical consultation targeting outpatients at the Fujita Health University Hospital (Japan) provides support to patients undergoing anticancer drug treatment. This study aimed to explore factors that affect the comprehension of cancer chemotherapy among outpatients who received cancer treatme...
Saved in:
| Published in | Biological & pharmaceutical bulletin Vol. 46; no. 3; pp. 505 - 510 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
The Pharmaceutical Society of Japan
01.03.2023
Japan Science and Technology Agency |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Pharmaceutical consultation targeting outpatients at the Fujita Health University Hospital (Japan) provides support to patients undergoing anticancer drug treatment. This study aimed to explore factors that affect the comprehension of cancer chemotherapy among outpatients who received cancer treatment at our hospital. A questionnaire survey was conducted, and comprehension was scored on a scale of 1–5 (1, no comprehension; 5, full comprehension). When factors other than age and sex [the influence of which on comprehension has been reported in previous reports] were noted, differences in comprehension between the questionnaire items were comparatively analyzed according to the presence/absence of the relevant factors. Overall, 536 patients were included. Age (<70 years) and pharmacist interventions were identified as factors contributing to a comprehension score. The levels of comprehension regarding the name of the cancer chemotherapy, content/schedule of the treatment, purposes of the prescribed drugs, and objectives of blood tests were significantly higher in the group that received the pharmaceutical interventions; conversely, the level of comprehension for the self-management of adverse events was significantly lower in this group than in the group that did not receive any pharmaceutical interventions. Age and interventions by the pharmacist affected the comprehension of cancer chemotherapy by patients. |
|---|---|
| AbstractList | Pharmaceutical consultation targeting outpatients at the Fujita Health University Hospital (Japan) provides support to patients undergoing anticancer drug treatment. This study aimed to explore factors that affect the comprehension of cancer chemotherapy among outpatients who received cancer treatment at our hospital. A questionnaire survey was conducted, and comprehension was scored on a scale of 1-5 (1, no comprehension; 5, full comprehension). When factors other than age and sex [the influence of which on comprehension has been reported in previous reports] were noted, differences in comprehension between the questionnaire items were comparatively analyzed according to the presence/absence of the relevant factors. Overall, 536 patients were included. Age (<70 years) and pharmacist interventions were identified as factors contributing to a comprehension score. The levels of comprehension regarding the name of the cancer chemotherapy, content/schedule of the treatment, purposes of the prescribed drugs, and objectives of blood tests were significantly higher in the group that received the pharmaceutical interventions; conversely, the level of comprehension for the self-management of adverse events was significantly lower in this group than in the group that did not receive any pharmaceutical interventions. Age and interventions by the pharmacist affected the comprehension of cancer chemotherapy by patients.Pharmaceutical consultation targeting outpatients at the Fujita Health University Hospital (Japan) provides support to patients undergoing anticancer drug treatment. This study aimed to explore factors that affect the comprehension of cancer chemotherapy among outpatients who received cancer treatment at our hospital. A questionnaire survey was conducted, and comprehension was scored on a scale of 1-5 (1, no comprehension; 5, full comprehension). When factors other than age and sex [the influence of which on comprehension has been reported in previous reports] were noted, differences in comprehension between the questionnaire items were comparatively analyzed according to the presence/absence of the relevant factors. Overall, 536 patients were included. Age (<70 years) and pharmacist interventions were identified as factors contributing to a comprehension score. The levels of comprehension regarding the name of the cancer chemotherapy, content/schedule of the treatment, purposes of the prescribed drugs, and objectives of blood tests were significantly higher in the group that received the pharmaceutical interventions; conversely, the level of comprehension for the self-management of adverse events was significantly lower in this group than in the group that did not receive any pharmaceutical interventions. Age and interventions by the pharmacist affected the comprehension of cancer chemotherapy by patients. Pharmaceutical consultation targeting outpatients at the Fujita Health University Hospital (Japan) provides support to patients undergoing anticancer drug treatment. This study aimed to explore factors that affect the comprehension of cancer chemotherapy among outpatients who received cancer treatment at our hospital. A questionnaire survey was conducted, and comprehension was scored on a scale of 1-5 (1, no comprehension; 5, full comprehension). When factors other than age and sex [the influence of which on comprehension has been reported in previous reports] were noted, differences in comprehension between the questionnaire items were comparatively analyzed according to the presence/absence of the relevant factors. Overall, 536 patients were included. Age (<70 years) and pharmacist interventions were identified as factors contributing to a comprehension score. The levels of comprehension regarding the name of the cancer chemotherapy, content/schedule of the treatment, purposes of the prescribed drugs, and objectives of blood tests were significantly higher in the group that received the pharmaceutical interventions; conversely, the level of comprehension for the self-management of adverse events was significantly lower in this group than in the group that did not receive any pharmaceutical interventions. Age and interventions by the pharmacist affected the comprehension of cancer chemotherapy by patients. |
| ArticleNumber | b22-00374 |
| Author | Nakasuji, Nayu Hayashi, Takahiro Yamada, Shigeki Kawada, Kenji Ando, Yosuke Tsujii, Naho Imaizumi, Kazuyoshi Nishibe-Toyosato, Seira Tsuge, Masahiro Ito, Kaori Matsuda, Hidezo |
| Author_xml | – sequence: 1 fullname: Nishibe-Toyosato, Seira organization: Department of Clinical Pharmacy, Fujita Health University School of Medicine – sequence: 2 fullname: Ando, Yosuke organization: Department of Clinical Pharmacy, Fujita Health University School of Medicine – sequence: 3 fullname: Nakasuji, Nayu organization: Department of Pharmacy, Fujita Health University Hospital – sequence: 4 fullname: Hayashi, Takahiro organization: Department of Clinical Pharmacy, Fujita Health University School of Medicine – sequence: 5 fullname: Ito, Kaori organization: Department of Pharmacy, Fujita Health University Hospital – sequence: 6 fullname: Matsuda, Hidezo organization: Department of Pharmacy, Fujita Health University Hospital – sequence: 7 fullname: Tsujii, Naho organization: Department of Pharmacy, Fujita Health University Hospital – sequence: 8 fullname: Tsuge, Masahiro organization: Department of Clinical Pharmacy, Fujita Health University School of Medicine – sequence: 9 fullname: Imaizumi, Kazuyoshi organization: Department of Respiratory Medicine, Fujita Health University School of Medicine – sequence: 10 fullname: Kawada, Kenji organization: Department of Medical Oncology, Fujita Health University School of Medicine – sequence: 11 fullname: Yamada, Shigeki organization: Department of Clinical Pharmacy, Fujita Health University School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36858580$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10U9rHCEcBmApKc0m7bHXMtBLL5P6ZxydYxiathBIKe1Z1P2ZdZnRqTqBfPu62XQPgSLowedV8b1AZyEGQOg9wVeEdvKzWcyVobTFmInuFdoQ1omWU8LP0AYPRLY94fIcXeS8xxgLTNkbdM56yevAG_TjRtsSU26unQNbfLhvyg6aMc5Lgh2E7GNoomvu1rLo4iGU3PwEC_7hQEcdLKRm3MEcayzp5fEteu30lOHd83qJft98-TV-a2_vvn4fr29b2-OhtCCcdmAY1pJaMoBjWBqJu84QznDPZU_tIICZwXEDzAox0K3GQnPtiLVbdok-Hc9dUvyzQi5q9tnCNOkAcc2KCkl6SgXllX58QfdxTaG-TlGJCcHdQLuqPjyr1cywVUvys06P6t9fVdAegU0x5wTuRAhWhy5U7ULVLtRTF9WzF976Uv8whpK0n_6bGo-pfS76Hk536FS8neBJd71ih-mUOu3anU4KAvsLwGmk8g |
| CitedBy_id | crossref_primary_10_1016_j_cpt_2025_02_006 |
| Cites_doi | 10.1177/1078155216655473 10.2146/ajhp130278 10.4103/apjon.apjon_35_17 10.1016/j.pec.2009.06.017 10.1200/JCO.2008.20.1293 10.1155/2020/4392058 10.3999/jscpt.47.62 10.1155/2015/502431 10.1016/S1470-2045(13)70604-1 10.1056/NEJMoa065044 10.1188/15.ONF.383-389 10.4103/1817-1737.109823 10.1200/JCO.2012.44.2806 10.1016/S1470-2045(16)30033-X 10.1177/1078155219833441 10.1248/yakushi.129.427 10.3892/ol.2014.2480 10.5649/jjphcs.36.880 10.2482/haigan.59.458 10.5649/jjphcs.38.599 10.1188/12.ONF.E373-E379 |
| ContentType | Journal Article |
| Copyright | 2023 The Pharmaceutical Society of Japan Copyright Japan Science and Technology Agency 2023 |
| Copyright_xml | – notice: 2023 The Pharmaceutical Society of Japan – notice: Copyright Japan Science and Technology Agency 2023 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7QR 7TK 7U9 8FD FR3 H94 P64 7X8 |
| DOI | 10.1248/bpb.b22-00374 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database AIDS and Cancer Research Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Virology and AIDS Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1347-5215 |
| EndPage | 510 |
| ExternalDocumentID | 36858580 10_1248_bpb_b22_00374 article_bpb_46_3_46_b22_00374_article_char_en |
| Genre | Journal Article General Information |
| GroupedDBID | --- 23N 2WC 5GY 6J9 ACGFO ACIWK ACPRK ADBBV AENEX AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BKOMP CS3 DIK DU5 E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH KQ8 MOJWN OK1 P2P RJT RZJ TR2 XSB AAYXX CITATION .55 1CY 53G ABJNI AI. CGR CUY CVF ECM EIF NPM TKC VH1 X7M ZXP ZY4 7QP 7QR 7TK 7U9 8FD FR3 H94 P64 7X8 |
| ID | FETCH-LOGICAL-c609t-e7fafeb30a82c19ef308b8044b153065862c97e3b9f5be3c7792da07a5af1ccd3 |
| ISSN | 0918-6158 1347-5215 |
| IngestDate | Fri Jul 11 07:50:47 EDT 2025 Mon Jun 30 09:59:04 EDT 2025 Mon Jul 21 06:05:25 EDT 2025 Thu Apr 24 23:05:27 EDT 2025 Tue Jul 01 02:44:04 EDT 2025 Thu Aug 17 20:30:03 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | patient comprehension age pharmaceutical consultation targeting outpatient outpatient cancer chemotherapy |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c609t-e7fafeb30a82c19ef308b8044b153065862c97e3b9f5be3c7792da07a5af1ccd3 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/bpb/46/3/46_b22-00374/_article/-char/en |
| PMID | 36858580 |
| PQID | 2801104924 |
| PQPubID | 1966364 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_2781622725 proquest_journals_2801104924 pubmed_primary_36858580 crossref_primary_10_1248_bpb_b22_00374 crossref_citationtrail_10_1248_bpb_b22_00374 jstage_primary_article_bpb_46_3_46_b22_00374_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-03-01 |
| PublicationDateYYYYMMDD | 2023-03-01 |
| PublicationDate_xml | – month: 03 year: 2023 text: 2023-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan – name: Tokyo |
| PublicationTitle | Biological & pharmaceutical bulletin |
| PublicationTitleAlternate | Biol Pharm Bull |
| PublicationYear | 2023 |
| Publisher | The Pharmaceutical Society of Japan Japan Science and Technology Agency |
| Publisher_xml | – name: The Pharmaceutical Society of Japan – name: Japan Science and Technology Agency |
| References | 12) Arakawa-Todo M, Yoshizawa T, Zennami K, Nishikawa G, Kato Y, Kobayashi I, Kajikawa K, Yamada Y, Matsuura K, Tsukiyama I, Saito H, Hasegawa T, Nakamura K, Sumitomo M. Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes. Anticancer Res., 33, 5043–5050 (2013). 1) Cancer Information Services, National Cancer Center, Japan: ‹https://ganjoho.jp/reg_stat/statistics/stat/annual.html›, accessed 19 May, 2022. 6) Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol., 15, 213–222 (2014). 4) Sommers RM, Miller K, Berry DL. Feasibility pilot on medication adherence and knowledge in ambulatory patients with gastrointestinal cancer. Oncol. Nurs. Forum, 39, E373–E379 (2012). 20) K. Imamura C. Evaluation of clinical response in cancer drug therapy. Jpn. J. Clin. Pharmacol. Ther., 47, 62–67 (2016). 24) Kimura M, Go M, Iwai M, Usami E, Teramachi H, Yoshimura T. Evaluation of the role and usefulness of a pharmacist outpatient service for patients undergoing monotherapy with oral anti-cancer agents. J. Oncol. Pharm. Pract., 23, 413–421 (2017). 25) Wang Y, Wu H, Xu F. Impact of clinical pharmacy services on KAP and QOL in cancer patients: a single-center experience. Biomed. Res. Int., 2015, 502431 (2015). 3) Tokdemir G, Kav S. The effect of structured education to patients receiving oral agents for cancer treatment on medication adherence and self-efficacy. Asia Pac. J. Oncol. Nurs., 4, 290–298 (2017). 16) Mekonnen GB, Gelayee DA. Low medication knowledge and adherence to oral chronic medications among patients attending community pharmacies: a cross-sectional study in a low-income country. Biomed Res. Int., 2020, 4392058 (2020). 8) Khrystolubova N, Shieh M, Patel AJ, Bailey R. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. J. Oncol. Pharm. Pract., 26, 13–22 (2020). 23) Iwakiri U, Kobayashi D, Kubota T, Suenaga K, Kamimura H, Shimazoe T. Cautions for pharmaceutical care in cancer patients—comparative evaluation between cancer and non–cancer. Gan To Kagaku Ryoho, 39, 1693–1697 (2012). 22) Nakajima K, Mano Y, Ohuchi K, Sato D, Iwata K, Higuchi A, Ebara K, Kato Y, Hirosawa K, Tajima M, Tsuchiya F, Yamada H, Kotaki H, Asahi M. Role of pharmaceutical outpatient clinic in cancer patients and evaluation. Jpn. J. Pharm. Health Care Sci., 38, 599–608 (2012). 18) Onda M, Sakurai H, Hayase Y, Sakamaki H, Arakawa Y, Yasukawa F. Effects of patient-pharmacist communication on the treatment of asthma. Yakugaku Zasshi, 129, 427–433 (2009). 17) Kimura M, Usami E, Iwai M, Nakao T, Yoshimura T, Mori H, Sugiyama T, Teramachi H. Oral anticancer agent medication adherence by outpatients. Oncol. Lett., 8, 2318–2324 (2014). 11) Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 27, 3584–3590 (2009). 13) Makihara K, Ohta M, Ueno H, Hama I. Effectiveness of interventions by pharmacists in ensuring safety and efficacy of outpatient chemotherapy prescription. Jpn. J. Pharm. Health Care Sci., 36, 880–886 (2010). 5) Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol., 31, 3327–3334 (2013). 7) Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol., 17, 577–589 (2016). 2) Boucher J, Lucca J, Hooper C, Pedulla L, Berry DL. A structured nursing intervention to address oral chemotherapy adherence in patients with non-small cell lung cancer. Oncol. Nurs. Forum, 42, 383–389 (2015). 10) Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon-α in metastatic renal cell carcinoma. N. Engl. J. Med., 356, 115–124 (2007). 14) Marks JR, Schectman JM, Groninger H, Plews-Ogan ML. The association of health literacy and socio-demographic factors with medication knowledge. Patient Educ. Couns., 78, 372–376 (2010). 19) Osawa T, Hasegawa T, Umeda M, Makino T, Aoyama S, Yasuda M, Mizui T, Yoshida T, Sawa T, Goto C. Impact of pharmaceutical counseling on chemotherapy-related anxiety in lung cancer patients. Japanese J. Lung Cancer, 59, 458–462 (2019). 9) Wong SF, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez E. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am. J. Health Syst. Pharm., 71, 960–965 (2014). 15) Alkatheri AM, Albekairy AM. Does the patients’ educational level and previous counseling affect their medication knowledge? Ann. Thorac. Med., 8, 105–108 (2013). 21) Shoji K, Kotani H, Ishikawa K, Ito M, Miyazaki M, Kiriyama N, Yamada S, Ando Y, Mori S, Mori A, Yamada K, Noda Y. Formulating instructions for outpatients based on research into adverse drug reactions induced by chemotherapy. Jpn. J. Pharm. Palliat. Care Sci., 4, 31–39 (2011). 22 23 24 25 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 21 |
| References_xml | – reference: 3) Tokdemir G, Kav S. The effect of structured education to patients receiving oral agents for cancer treatment on medication adherence and self-efficacy. Asia Pac. J. Oncol. Nurs., 4, 290–298 (2017). – reference: 5) Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol., 31, 3327–3334 (2013). – reference: 8) Khrystolubova N, Shieh M, Patel AJ, Bailey R. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. J. Oncol. Pharm. Pract., 26, 13–22 (2020). – reference: 7) Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol., 17, 577–589 (2016). – reference: 16) Mekonnen GB, Gelayee DA. Low medication knowledge and adherence to oral chronic medications among patients attending community pharmacies: a cross-sectional study in a low-income country. Biomed Res. Int., 2020, 4392058 (2020). – reference: 9) Wong SF, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez E. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am. J. Health Syst. Pharm., 71, 960–965 (2014). – reference: 23) Iwakiri U, Kobayashi D, Kubota T, Suenaga K, Kamimura H, Shimazoe T. Cautions for pharmaceutical care in cancer patients—comparative evaluation between cancer and non–cancer. Gan To Kagaku Ryoho, 39, 1693–1697 (2012). – reference: 18) Onda M, Sakurai H, Hayase Y, Sakamaki H, Arakawa Y, Yasukawa F. Effects of patient-pharmacist communication on the treatment of asthma. Yakugaku Zasshi, 129, 427–433 (2009). – reference: 12) Arakawa-Todo M, Yoshizawa T, Zennami K, Nishikawa G, Kato Y, Kobayashi I, Kajikawa K, Yamada Y, Matsuura K, Tsukiyama I, Saito H, Hasegawa T, Nakamura K, Sumitomo M. Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes. Anticancer Res., 33, 5043–5050 (2013). – reference: 22) Nakajima K, Mano Y, Ohuchi K, Sato D, Iwata K, Higuchi A, Ebara K, Kato Y, Hirosawa K, Tajima M, Tsuchiya F, Yamada H, Kotaki H, Asahi M. Role of pharmaceutical outpatient clinic in cancer patients and evaluation. Jpn. J. Pharm. Health Care Sci., 38, 599–608 (2012). – reference: 24) Kimura M, Go M, Iwai M, Usami E, Teramachi H, Yoshimura T. Evaluation of the role and usefulness of a pharmacist outpatient service for patients undergoing monotherapy with oral anti-cancer agents. J. Oncol. Pharm. Pract., 23, 413–421 (2017). – reference: 17) Kimura M, Usami E, Iwai M, Nakao T, Yoshimura T, Mori H, Sugiyama T, Teramachi H. Oral anticancer agent medication adherence by outpatients. Oncol. Lett., 8, 2318–2324 (2014). – reference: 19) Osawa T, Hasegawa T, Umeda M, Makino T, Aoyama S, Yasuda M, Mizui T, Yoshida T, Sawa T, Goto C. Impact of pharmaceutical counseling on chemotherapy-related anxiety in lung cancer patients. Japanese J. Lung Cancer, 59, 458–462 (2019). – reference: 2) Boucher J, Lucca J, Hooper C, Pedulla L, Berry DL. A structured nursing intervention to address oral chemotherapy adherence in patients with non-small cell lung cancer. Oncol. Nurs. Forum, 42, 383–389 (2015). – reference: 15) Alkatheri AM, Albekairy AM. Does the patients’ educational level and previous counseling affect their medication knowledge? Ann. Thorac. Med., 8, 105–108 (2013). – reference: 1) Cancer Information Services, National Cancer Center, Japan: ‹https://ganjoho.jp/reg_stat/statistics/stat/annual.html›, accessed 19 May, 2022. – reference: 14) Marks JR, Schectman JM, Groninger H, Plews-Ogan ML. The association of health literacy and socio-demographic factors with medication knowledge. Patient Educ. Couns., 78, 372–376 (2010). – reference: 11) Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 27, 3584–3590 (2009). – reference: 4) Sommers RM, Miller K, Berry DL. Feasibility pilot on medication adherence and knowledge in ambulatory patients with gastrointestinal cancer. Oncol. Nurs. Forum, 39, E373–E379 (2012). – reference: 13) Makihara K, Ohta M, Ueno H, Hama I. Effectiveness of interventions by pharmacists in ensuring safety and efficacy of outpatient chemotherapy prescription. Jpn. J. Pharm. Health Care Sci., 36, 880–886 (2010). – reference: 20) K. Imamura C. Evaluation of clinical response in cancer drug therapy. Jpn. J. Clin. Pharmacol. Ther., 47, 62–67 (2016). – reference: 21) Shoji K, Kotani H, Ishikawa K, Ito M, Miyazaki M, Kiriyama N, Yamada S, Ando Y, Mori S, Mori A, Yamada K, Noda Y. Formulating instructions for outpatients based on research into adverse drug reactions induced by chemotherapy. Jpn. J. Pharm. Palliat. Care Sci., 4, 31–39 (2011). – reference: 25) Wang Y, Wu H, Xu F. Impact of clinical pharmacy services on KAP and QOL in cancer patients: a single-center experience. Biomed. Res. Int., 2015, 502431 (2015). – reference: 10) Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon-α in metastatic renal cell carcinoma. N. Engl. J. Med., 356, 115–124 (2007). – reference: 6) Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol., 15, 213–222 (2014). – ident: 12 – ident: 24 doi: 10.1177/1078155216655473 – ident: 9 doi: 10.2146/ajhp130278 – ident: 3 doi: 10.4103/apjon.apjon_35_17 – ident: 14 doi: 10.1016/j.pec.2009.06.017 – ident: 11 doi: 10.1200/JCO.2008.20.1293 – ident: 16 doi: 10.1155/2020/4392058 – ident: 20 doi: 10.3999/jscpt.47.62 – ident: 25 doi: 10.1155/2015/502431 – ident: 6 doi: 10.1016/S1470-2045(13)70604-1 – ident: 10 doi: 10.1056/NEJMoa065044 – ident: 1 – ident: 2 doi: 10.1188/15.ONF.383-389 – ident: 15 doi: 10.4103/1817-1737.109823 – ident: 5 doi: 10.1200/JCO.2012.44.2806 – ident: 7 doi: 10.1016/S1470-2045(16)30033-X – ident: 8 doi: 10.1177/1078155219833441 – ident: 18 doi: 10.1248/yakushi.129.427 – ident: 17 doi: 10.3892/ol.2014.2480 – ident: 13 doi: 10.5649/jjphcs.36.880 – ident: 19 doi: 10.2482/haigan.59.458 – ident: 22 doi: 10.5649/jjphcs.38.599 – ident: 21 – ident: 4 doi: 10.1188/12.ONF.E373-E379 – ident: 23 |
| SSID | ssj0007023 |
| Score | 2.3808882 |
| Snippet | Pharmaceutical consultation targeting outpatients at the Fujita Health University Hospital (Japan) provides support to patients undergoing anticancer drug... |
| SourceID | proquest pubmed crossref jstage |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 505 |
| SubjectTerms | Age Aged Antitumor agents Cancer Chemotherapy Hospitals, University Humans Neoplasms outpatient cancer chemotherapy Outpatients patient comprehension Patients pharmaceutical consultation targeting outpatient Pharmaceutical Preparations Pharmaceuticals Pharmacists Questionnaires |
| Title | Factors Affecting the Comprehension of Outpatients Receiving Cancer Chemotherapy |
| URI | https://www.jstage.jst.go.jp/article/bpb/46/3/46_b22-00374/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/36858580 https://www.proquest.com/docview/2801104924 https://www.proquest.com/docview/2781622725 |
| Volume | 46 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Biological and Pharmaceutical Bulletin, 2023/03/01, Vol.46(3), pp.505-510 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgINgLgo6PwkBGQn2hKanz4UTipaqYJiTGHjppPEW246zZWFK1zUP46znbiZMClYAXq7IvH8rv5-ud7btD6J0XSaBFyhzqpdzxaZo6kT9lThSmGeEiTKc6mc6Xs_D0wv98GVx2x4p0dMmWT8SPP8aV_A-q0Ae4qijZf0DW3hQ64DfgCy0gDO1fYXzSFMuZ6UMZbeCTmuJruVQn040x-LXaNulTVVCIkLleRJgrvNfvVcaAJgprd4c3t2pRsWO13Fn75v2s3WZbY5lz6SzKutwwXZoJ1FC-tkp_VqS681u5qW4smc7YDdtU17nR83XV6cNaFXnSZAKRZb4u-8sTxOvOZ02kUameT8HdNUGbrc5tlh3zvkuuFWigg7B_V-zEV8EKfMUnHLxnnTWnLwe4rG41yiahvqkO9Usm7XboLrpHwKkgWo13zhKFt2-ysMLTPuw86xA9aK_eMWDuX4MNfyX3uyfaTFk8Ro8a_wLPDFmeoDuyGKCjWQGY3NZ4hPWJX72VMkAP5221vwEanRuA6zFedCF5m7G-xGY3r4_QeUM6bEmHgT14h3S4zHCPdNiSDhvS4T7pnqKLk0-L-anTlOVwROjGW0fSjGWSey6LiJjGMvPciEeu73P491QWbUhETKXH4yzg0hOUxiRlLmUBy6ZCpN4zdFCUhXyBMItdkfoy9TzC1coCm6Y0FAKs6iCIeEyGaNx-60Q0OetV6ZTvifJdAaUEUEoApUSjNEQjK74yyVr2CX40wFmxZg5rMT9MPNVYcTuqIiFB8QzRcQt30qiDTUIiZUr7MYG7v7XDgKLagWOFLCuQodE0JISSYIieG5rYN2j59XLvyCt02M2wY3SwXVfyNZjEW_5GM_kn2m26mw |
| linkProvider | ABC ChemistRy |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+Affecting+the+Comprehension+of+Outpatients+Receiving+Cancer+Chemotherapy&rft.jtitle=Biological+%26+pharmaceutical+bulletin&rft.au=Nishibe-Toyosato%2C+Seira&rft.au=Ando%2C+Yosuke&rft.au=Nakasuji%2C+Nayu&rft.au=Hayashi%2C+Takahiro&rft.date=2023-03-01&rft.eissn=1347-5215&rft.volume=46&rft.issue=3&rft.spage=505&rft_id=info:doi/10.1248%2Fbpb.b22-00374&rft_id=info%3Apmid%2F36858580&rft.externalDocID=36858580 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-6158&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-6158&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-6158&client=summon |